A functional single nucleotide polymorphisms in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 1, 2004, Pages 54-57

  Kremer Hovinga, J A ^a,f   Franco, R F ^b   Zago, M A ^c   Ten Cate, Hugo ^a,d   Westendorp, R G J ^e   Reitsma, P H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Fleury   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

Fibrinolysis; Meningococcal disease outcome; Single nucleotide polymorphism; TAFI

Indexed keywords

DNA; FIBRIN; ISOLEUCINE; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; PRIMER DNA;

ARTICLE; ATTENUATION; BLOOD CLOTTING; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DNA POLYMORPHISM; FIBRIN DEPOSITION; FIBRINOLYSIS; GENE ACTIVITY; GENE FREQUENCY; GENE FUNCTION; GENETIC RISK; GENETIC STABILITY; GENETIC VARIABILITY; GENOTYPE; GRAM NEGATIVE SEPSIS; HUMAN; MENINGOCOCCOSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RELATIVE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOGENESIS; ALLELE; CASE CONTROL STUDY; ENZYMOLOGY; FEMALE; GENETICS; MALE; NUCLEOTIDE SEQUENCE;

ALLELES; BASE SEQUENCE; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 4444246103     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00557.x     Document Type: Article

References (31)

1. de Kleijn ED, Hazelzet JA, Kornelisse RF, de Groot R. Pathophysiology of meningococcal sepsis in children. Eur J Pediatr 1998; 157: 869-80.
2. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344: 1378-88.
3. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998; 24: 33-44.
4. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
5. Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F, Kruithof EK. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-62.
6. Brandtzaeg P, Joo GB, Brusletto B, Kierulf P. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990; 57: 271-8.
7. Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, Garcia-Avello A. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103: 1536-42.
8. Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354: 561-3.
9. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet 1999; 354: 556-60.
10. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 386-91.
11. Bouma BN, dem Borne PA, Meijers JC. Factor XI and protection of the fibrin clot against lysis: a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost 1998; 80: 24-7.
12. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
13. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273 27176-81.
14. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Stromqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
15. Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000; 275 12868-78.
16. Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JC, Bouma BN. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 12410-5.
17. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-8.
18. Franco RF, Fagundes MG, Meijers JC, Reitsma PH, Lourenco D, Morelli V, Maffei FH, Ferrari IC, Piccinato CE, Silva Jr WA, Zago MA. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma tafi levels and risk of venous thrombosis. Haematologica 2001; 86: 510-7.
19. Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost 1998; 80: 949-55.
20. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr 325 and Ile 325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277 1021-30.
21. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320 1165-72.
22. van Deventer SJ, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-6.
23. Hoyne AL, Brown RH. 727 Meningococcic cases, an analysis. Ann Int Med 1948; 28: 248-59.
24. van Deuren M, van Dijke BJ, Koopman RJ, Horrevorts AM, Meis JF, Santman FW, van der Meer JW. Rapid diagnosis of acute meningococcal infections by needle aspiration or biopsy of skin lesions. Br Med J 1993; 306: 1229-32.
25. Brouwers GJ, Vos HL, Leebeek FW, Bulk S, Schneider M, Boffa M, Koschinsky M, van Tilburg NH, Nesheim ME, Bertina RM, Gomez Garcia EB. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001; 98: 1992-3.
26. Tsuboi Y, Takahashi M, Ishikawa Y, Okada H, Yamada T. Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy. Ther Apher 1998; 2: 297-9.
27. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78: 2249-52.
28. Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2792-8.
29. Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85: 5-11.
30. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-30.
31. Wang W, Nagashima M, Schneider M, Morser J, Nesheim M. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem 2000; 275: 22942-7.